{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:00:15Z","timestamp":1786993215833,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2BX005218"],"award-info":[{"award-number":["IK2BX005218"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX004868"],"award-info":[{"award-number":["I01BX004868"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jpet.2025.103698","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:46:49Z","timestamp":1757375209000},"page":"103698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The \u03b22-adrenoceptor agonist formoterol reverses metabolic dysfunction in the diabetic proximal tubule"],"prefix":"10.1016","volume":"392","author":[{"given":"Kristan H.","family":"Cleveland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-5482","authenticated-orcid":false,"given":"Natalie E.","family":"Scholpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick G.","family":"Schnellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"600","key":"10.1016\/j.jpet.2025.103698_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd2699","article-title":"Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes","volume":"13","author":"Md Dom","year":"2021","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jpet.2025.103698_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00806915","article-title":"Amino acids and the kidney","volume":"1","author":"Young","year":"1991","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/nu15010184","article-title":"Metabolic homeostasis of amino acids and diabetic kidney disease","volume":"15","author":"Liu","year":"2022","journal-title":"Nutrients"},{"issue":"16","key":"10.1016\/j.jpet.2025.103698_bib4","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.3390\/nu14163345","article-title":"Impaired amino acid metabolism and its correlation with diabetic kidney disease progression in type 2 diabetes mellitus","volume":"14","author":"Zhu","year":"2022","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.jpet.2025.103698_bib5","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1172\/JCI44442","article-title":"Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans","volume":"121","author":"Rhee","year":"2011","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.jpet.2025.103698_bib6","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1007\/s00125-017-4325-0","article-title":"Early metabolic markers identify potential targets for the prevention of type 2 diabetes","volume":"60","author":"Peddinti","year":"2017","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jpet.2025.103698_bib7","doi-asserted-by":"crossref","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","article-title":"The proximal tubule in the pathophysiology of the diabetic kidney","volume":"300","author":"Vallon","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jpet.2025.103698_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-physiol-020911-153333","article-title":"Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney","volume":"74","author":"Vallon","year":"2012","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103698_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103698_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/pharmrev.122.000560","article-title":"Pharmacological targeting of mitochondria in diabetic kidney disease","volume":"75","author":"Cleveland","year":"2023","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.jpet.2025.103698_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2362.2004.01429.x","article-title":"New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology","volume":"34","author":"Wolf","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.jpet.2025.103698_bib12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/01.ASN.0000065640.77499.D7","article-title":"Extracellular matrix metabolism in diabetic nephropathy","volume":"14","author":"Mason","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jpet.2025.103698_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.pathol.4.110807.092150","article-title":"A glimpse of various pathogenetic mechanisms of diabetic nephropathy","volume":"6","author":"Kanwar","year":"2011","journal-title":"Annu Rev Pathol"},{"issue":"15","key":"10.1016\/j.jpet.2025.103698_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86976","article-title":"Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications","volume":"1","author":"Sas","year":"2016","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.jpet.2025.103698_bib15","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/db08-0057","article-title":"Oxidative stress as a major culprit in kidney disease in diabetes","volume":"57","author":"Forbes","year":"2008","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1096\/fasebj.13.1.23","article-title":"Contributions of polyol pathway to oxidative stress in diabetic cataract","volume":"13","author":"Lee","year":"1999","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.jpet.2025.103698_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semnephrol.2018.01.002","article-title":"The Warburg effect in diabetic kidney disease","volume":"38","author":"Zhang","year":"2018","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jpet.2025.103698_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ki.2013.462","article-title":"Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury","volume":"85","author":"Decleves","year":"2014","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.jpet.2025.103698_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.P040501","article-title":"Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy","volume":"55","author":"Herman-Edelstein","year":"2014","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.jpet.2025.103698_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF00515567","article-title":"Beta-adrenoceptor subtypes in sections of rat and guinea-pig kidney","volume":"328","author":"Engel","year":"1985","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1152\/physrev.1997.77.1.75","article-title":"Neural control of renal function","volume":"77","author":"DiBona","year":"1997","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.jpet.2025.103698_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1523-1755.2001.059002515.x","article-title":"Immunofluorescent imaging of beta 1- and beta 2-adrenergic receptors in rat kidney","volume":"59","author":"Boivin","year":"2001","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.jpet.2025.103698_bib24","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1681\/ASN.2013090952","article-title":"Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury","volume":"25","author":"Jesinkey","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103698_bib25","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.kint.2019.03.023","article-title":"Mitochondrial biogenesis induced by the beta2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury","volume":"96","author":"Arif","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.kint.2017.02.013","article-title":"Beta 2-adrenergic receptor agonists are novel regulators of macrophage activation in diabetic renal and cardiovascular complications","volume":"92","author":"Noh","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.118.252833","article-title":"Proximal Tubule beta 2-adrenergic receptor mediates formoterol-induced recovery of mitochondrial and renal function after ischemia-reperfusion injury","volume":"369","author":"Cameron","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.jpet.2025.103698_bib28","doi-asserted-by":"crossref","first-page":"F773","DOI":"10.1152\/ajprenal.00427.2020","article-title":"Regulation of mitochondrial dynamics and energetics in the diabetic renal proximal tubule by the beta2-adrenergic receptor agonist formoterol","volume":"319","author":"Cleveland","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jpet.2025.103698_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115436","article-title":"The beta(2)-adrenergic receptor agonist formoterol restores mitochondrial homeostasis in glucose-induced renal proximal tubule injury through separate integrated pathways","volume":"209","author":"Cleveland","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103698_bib30","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1681\/ASN.2009070721","article-title":"Mouse models of diabetic nephropathy","volume":"20","author":"Brosius","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103698_bib31","doi-asserted-by":"crossref","first-page":"F1138","DOI":"10.1152\/ajprenal.00315.2002","article-title":"Diabetic kidney disease in the db\/db mouse","volume":"284","author":"Sharma","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103698_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/10915818221099126","article-title":"NEW: Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 1: Principles and Practice of Toxicologic Pathology, 4th Edition - 2021","volume":"41","author":"Haschek-Hock","year":"2022","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.jpet.2025.103698_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2051-5960-1-18","article-title":"Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and alpha-KG","volume":"1","author":"Navis","year":"2013","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"10.1016\/j.jpet.2025.103698_bib34","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jpet.2025.103698_bib35","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3389\/fphys.2019.01460","article-title":"Differential impact of dietary branched chain and aromatic amino acids on chronic kidney disease progression in rats","volume":"10","author":"Pillai","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jpet.2025.103698_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113222","article-title":"SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db\/db mice","volume":"152","author":"Gong","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jpet.2025.103698_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/698567","article-title":"Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease","volume":"2013","author":"Syed Ikmal","year":"2013","journal-title":"Int J Endocrinol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103698_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.168825","article-title":"Glycolytic lactate in diabetic kidney disease","volume":"9","author":"Darshi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jpet.2025.103698_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.abb.2018.03.042","article-title":"Metabolic changes in urine and serum during progression of diabetic kidney disease in a mouse model","volume":"646","author":"Kim","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jpet.2025.103698_bib40","article-title":"Multi-omics analysis reveals the pathogenesis of db\/db mice diabetic kidney disease and the treatment mechanisms of multi-bioactive compounds combination from Salvia miltiorrhiza","volume":"13","author":"Xu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2025.103698_bib41","article-title":"Unraveling the nexus of NAD+ metabolism and diabetic kidney disease: insights from murine models and human data","volume":"15","author":"Yang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s44324-025-00067-0","article-title":"The role of NAD(+) metabolism and its modulation of mitochondria in aging and disease","volume":"3","author":"Yusri","year":"2025","journal-title":"NPJ Metab Health Dis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11030-5","article-title":"Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol","volume":"7","author":"Cameron","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jpet.2025.103698_bib44","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00125-020-05171-y","article-title":"Treatment with a beta-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity","volume":"63","author":"Kalinovich","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jpet.2025.103698_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nmd.2006.08.012","article-title":"Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue","volume":"17","author":"Harcourt","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.jpet.2025.103698_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107036","article-title":"What the BTBR\/J mouse has taught us about diabetes and diabetic complications","volume":"26","author":"Keller","year":"2023","journal-title":"iScience"},{"issue":"9","key":"10.1016\/j.jpet.2025.103698_bib47","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1681\/ASN.2009121290","article-title":"BTBR Ob\/Ob mutant mice model progressive diabetic nephropathy","volume":"21","author":"Hudkins","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jpet.2025.103698_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-pharmtox-010715-103155","article-title":"Mitochondrial biogenesis as a pharmacological target: a new approach to acute and chronic diseases","volume":"56","author":"Whitaker","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525399118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525399118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:58:11Z","timestamp":1761850691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525399118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0022356525399118"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103698","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u03b22-adrenoceptor agonist formoterol reverses metabolic dysfunction in the diabetic proximal tubule","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103698"}}